Related Experiment Videos
Current and novel immunosuppressive therapy for autoimmune hepatitis
Michael A Heneghan1, Ian G McFarlane
1Division of Gastroenterology, Duke University Medical Center, Durham NC 27710, USA. heneg003@mc.duke.edu
Hepatology (Baltimore, Md.)
|January 12, 2002
Summary
Corticosteroids and azathioprine effectively induce remission in over 80% of autoimmune hepatitis (AIH) patients. Continued immunosuppression is vital for maintaining remission and preventing relapse, with liver biopsy guiding treatment decisions.
Area of Science:
- Hepatology
- Immunology
- Gastroenterology
Background:
- Autoimmune hepatitis (AIH) is a chronic liver disease.
- Corticosteroids and azathioprine are standard first-line treatments for AIH.
- Remission induction rates exceed 80% with current therapies.
Purpose of the Study:
- To review current management strategies for AIH.
- To evaluate novel immunosuppressive agents for AIH treatment.
- To discuss the role of liver biopsy in AIH management.
Main Methods:
- Literature review of current AIH management strategies.
- Analysis of data on novel immunosuppressive agents.
- Evaluation of diagnostic and monitoring tools, including liver biopsy.
Main Results:
- Standard therapy (corticosteroids +/- azathioprine) achieves high remission rates.
- Sustained immunosuppression is crucial for preventing relapse.
- Liver biopsy is essential for assessing treatment response and need for therapy.
- Alternative agents like cyclosporine, tacrolimus, and mycophenolate mofetil are options for refractory cases.
- Liver transplantation is indicated for decompensated AIH.
Conclusions:
- Current therapies are effective but require careful monitoring.
- Novel immunosuppressive agents offer alternatives for treatment-resistant AIH.
- Personalized treatment approaches, guided by clinical and histological data, are essential for optimal AIH management.